share_log

Regeneron Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Regeneron Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

再生元制药公司 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/31 06:21

Moomoo AI 已提取核心信息

Regeneron Pharmaceuticals reported robust Q3 2024 financial results, with total revenue increasing 11% to $3.72 billion and net income rising 33% to $1.34 billion compared to Q3 2023. EYLEA HD and EYLEA U.S. net product sales grew to $1.54 billion, while global Dupixent sales surged 23% to $3.82 billion. Operating expenses increased 13% to $2.54 billion, reflecting higher R&D and commercialization investments.The company continued to advance its pipeline with multiple regulatory milestones. EYLEA HD received approvals in the EU and Japan for wet AMD and DME. Dupixent was approved in the U.S. for COPD and adolescent CRSwNP. However, the FDA issued Complete Response Letters for odronextamab in lymphoma and linvoseltamab in multiple myeloma due to manufacturing facility inspection findings.Looking ahead, Regeneron maintains a strong financial position with $18.3 billion in cash and investments as of September 30, 2024. The company authorized a new $3.0 billion share repurchase program in April 2024, with $2.89 billion remaining available. Key upcoming catalysts include Phase 3 QUASAR study results for EYLEA HD in RVO and regulatory decisions for multiple product candidates.
Regeneron Pharmaceuticals reported robust Q3 2024 financial results, with total revenue increasing 11% to $3.72 billion and net income rising 33% to $1.34 billion compared to Q3 2023. EYLEA HD and EYLEA U.S. net product sales grew to $1.54 billion, while global Dupixent sales surged 23% to $3.82 billion. Operating expenses increased 13% to $2.54 billion, reflecting higher R&D and commercialization investments.The company continued to advance its pipeline with multiple regulatory milestones. EYLEA HD received approvals in the EU and Japan for wet AMD and DME. Dupixent was approved in the U.S. for COPD and adolescent CRSwNP. However, the FDA issued Complete Response Letters for odronextamab in lymphoma and linvoseltamab in multiple myeloma due to manufacturing facility inspection findings.Looking ahead, Regeneron maintains a strong financial position with $18.3 billion in cash and investments as of September 30, 2024. The company authorized a new $3.0 billion share repurchase program in April 2024, with $2.89 billion remaining available. Key upcoming catalysts include Phase 3 QUASAR study results for EYLEA HD in RVO and regulatory decisions for multiple product candidates.
再生元制药公司发布了2024年第三季度强劲的财务结果，总营业收入增长了11%，达到37.2亿，净利润相比于2023年第三季度上升33%，达到13.4亿。EYLEA HD和EYLEA美国的净产品销售额增长至15.4亿，而全球Dupixent的销售额飙升23%，达到38.2亿。营业费用增长了13%，达到25.4亿，反映出在研发和商业化投资方面的增加。该公司继续推进其项目管线，取得了多个监管里程碑。EYLEA HD在欧盟和日本获得了对湿性黄斑变性和糖尿病性水肿的批准。Dupixent在美国获得了对慢性阻塞性肺病和青少年慢性鼻窦炎多发性息肉的批准。然而，由于制造设施检查结果，FDA对odronexta...展开全部
再生元制药公司发布了2024年第三季度强劲的财务结果，总营业收入增长了11%，达到37.2亿，净利润相比于2023年第三季度上升33%，达到13.4亿。EYLEA HD和EYLEA美国的净产品销售额增长至15.4亿，而全球Dupixent的销售额飙升23%，达到38.2亿。营业费用增长了13%，达到25.4亿，反映出在研发和商业化投资方面的增加。该公司继续推进其项目管线，取得了多个监管里程碑。EYLEA HD在欧盟和日本获得了对湿性黄斑变性和糖尿病性水肿的批准。Dupixent在美国获得了对慢性阻塞性肺病和青少年慢性鼻窦炎多发性息肉的批准。然而，由于制造设施检查结果，FDA对odronextamab在淋巴瘤和linvoseltamab在多发性骨髓瘤的申请发出了完整响应函。展望未来，再生元维持强劲的财务状况，截至2024年9月30日现金和投资总额为183亿。该公司在2024年4月授权了一项新的30亿的股份回购计划，还有28.9亿可用。即将到来的关键催化剂包括EYLEA HD在视网膜静脉阻塞的第三阶段QUASAR研究结果以及多个产品候选人的监管决策。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 114.650
    ABVC BioPharma
    ABVC
    -- 1.0800
    bluebird bio
    BLUE
    -- 4.930
    NLS Pharmaceutics
    NLSP
    -- 1.5700
    DBV Technologies
    DBVT
    -- 6.968
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点